Interpretation of World Health Organization’s Key updates to the treatment of drug-resistant tuberculosis: rapid communication

doi:10.19982/j.issn.1000-6621.20240422

Chinese Journal of Antituberculosis ›› 2024, Vol. 46 ›› Issue (11): 1303-1305.doi: 10.19982/j.issn.1000-6621.20240422

• Interpretation of Standards • Previous Articles Next Articles

Interpretation of World Health Organization’s Key updates to the treatment of drug-resistant tuberculosis: rapid communication

Wang Yutong¹^,², Liu Yuhong¹^,²()

¹Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
²Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

Received:2024-09-24 Online:2024-11-10 Published:2024-10-31
Contact: Liu Yuhong, Email: liuyuhong0516@126.com
Supported by:
Beijing Municipal Health Commission High Level Public Health Talent Construction Project (Discipline Leader 03-11);Beijing Hospitals Authority Ascent Plan(DFL20191601);Beijing Hospitals Authority Ascent Plan(DFL20221401)

Abstract

Abstract:

In June 2024, the World Health Organization issued Key updates to the treatment of drug-resistant tuberculosis: rapid communication, recommending a new 6-month BPaL-based regimen with levofloxacin or clofazimine or both, based on new clinical trial evidence. And a nine-month protocol for the treatment of multidrug-/rifampicin-resistant tuberculosis that is fluoroquinolone-sensitive, with the aim of notifying major updates ahead of the official release of the new guidelines for the treatment of drug-resistant tuberculosis. This article interprets the main updates in the notice for the reference of professionals in related fields.

Key words: Tuberculosis, Drug resistance, Therapeutic uses, Consensus development conferences as topic

CLC Number:

Wang Yutong, Liu Yuhong. Interpretation of World Health Organization’s Key updates to the treatment of drug-resistant tuberculosis: rapid communication[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1303-1305. doi: 10.19982/j.issn.1000-6621.20240422

[1]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[2]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[3]	World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Geneva: World Health Organization, 2024.
[4]	段鸿飞. 世界卫生组织对BPaLM方案治疗耐多药结核病指南的解读. 中国医学前沿杂志(电子版), 2024, 16(3):1-4. doi:10.12037/YXQY.2024.03-01.
[5]	Guglielmetti L, Khan U, Velásquez GE, et al. Nine-month, all-oral regimens for rifampin-resistant tuberculosis. medRxiv, 2024. doi:10.1101/2024.01.29.24301679.

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.

Interpretation of World Health Organization’s Key updates to the treatment of drug-resistant tuberculosis: rapid communication

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 5

Related Articles 15

Recommended Articles

Metrics

Comments